Attovia Therapeutics extended biotech IPO momentum with a $289 million listing, bringing new capital for development of its anti-itch immunology programs. The company said the proceeds will fund clinical-stage work targeting itch-driving pathways and accelerate progression toward broader proof points in multiple indications. The upsized debut reflects strong market demand for next-generation immunology assets, particularly those aimed at differentiated symptomatic relief where trial endpoints can translate quickly to commercial expectations. For investors tracking the IPO window, Attovia’s listing adds to the concentration of immunology and inflammation startups converting early pipeline progress into public-market funding.